AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Article
April 8, 2020
Open Access

Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS

Liliana E. Lucca, PhD, Benjamin A. Lerner, MD, Calvin Park, BA, Danielle DeBartolo, MS, Brian Harnett, BA, Varun P. Kumar, MD, Gerald Ponath, PhD, Khadir Raddassi, PhD, Anita Huttner, MD, David A. Hafler, MD, and David Pitt, MDAuthors Info & Affiliations
May 2020 issue
7 (3)
https://doi.org/10.1212/NXI.0000000000000712
Letters to the Editor
Track CitationsAdd to favorites
Full Text HTML

Information & Authors

Information

Published In

Neurology® Neuroimmunology & Neuroinflammation
Volume 7 • Number 3 • May 2020
PubMed: 32269065

Copyright

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Publication History

Received: April 1, 2019
Accepted: February 7, 2020
Published online: April 8, 2020
Published in issue: May 2020

Permissions

Request permissions for this article.

Disclosure

Dr. Hafler has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. In the past 10 years, he has been a consultant for Bayer Pharmaceuticals, Biohaven Pharmaceutical, Bristol-Myers Squibb, Compass Therapeutics, Eisai Pharmaceuticals, EMD Serono, Genentech, Juno Therapeutics, McKinsey&Co., MedImmune/AstraZeneca, Mylan Pharmaceuticals, NeuroPhage Pharmaceuticals, NKT Therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Questcor Pharmaceuticals, Roche, Sage Therapeutics, Sanofi Genzyme, Toray Industries, and Versant Venture. Dr. Lucca, Dr. Lerner, Mr. Park, Ms. DeBartolo, Mr. Harnett, Dr. Kumar, Dr. Ponath, Dr. Raddassi, Dr. Huttner, and Dr. Pitt report no disclosures. Go to Neurology.org/NN for full disclosures.

Study Funding

This works was funded by the National Multiple Sclerosis Society (RG 4866-A-2), the Gregory M. Kiez and Mehmet Kutman Foundation, and NIH Grants P01 AI045757 (DP) and NIH U19 AI089992, P01 AI073748, U24AI11867, R0AI22220, UM1HG009390, P01 AI039671, P50CA121974, the Nancy Taylor Foundation for Chronic Diseases, and NMSS grants RG-1802-30153CA and 1061-A-18 (DAH).

Authors

Affiliations & Disclosures

Liliana E. Lucca, PhD*
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
National Multiple Sclerosis Society Fellowship
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Benjamin A. Lerner, MD*
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Calvin Park, BA
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Danielle DeBartolo, MS
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Brian Harnett, BA
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Varun P. Kumar, MD
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Gerald Ponath, PhD
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Khadir Raddassi, PhD
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Anita Huttner, MD
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David A. Hafler, MD
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno Therapeutics, Proclara Biosciences, Roche, Sanofi Genzyme.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Received funding for trip expenses from (1) Genentech, (2) Federation of Clinical Immunology Societies, (3) Elsevier Publishing, (4) FP Pharmaceutical, (5) Boehringer-Ingleheim, (6) Nature Publishing Group, (7) McGill University, (8) Johns Hopkins University, (9) Keystone Symposia, (10) Alliance for Lupus Research, (11) American College of Rheumatology, (12) Eureka Institute for Translational Medicine, (13) Brown University, (14) NeuroPhage, (15) University of Virginia, (16) Foundation for Neurologic Diseases, (17) Letters & Sciences, (18) Weill Cornell Medical College, (19) Juvenile Diabetes Research Foundation, (20) Georgia Health Sciences University, (21) Cleveland Clinic, (22) Keystone Symposia, (23) Royal Swedish Academy of Sciences, (24) MedImmmune, (25) Mylan Pharmaceuticals, (26) Novartis, (27) Consortium of Multiple Sclerosis Centers, (28) Serono Symposia, (29) EUREKA Board Mtg, (30) Progressive MS Alliance Industry Forum, (31) Human Immunology Forum, (32) Istanbul MS Days, (33) New England Immunology Conference, (34) ECTRIMS, (35) Complex Systems Science & Immunology, (36) Nancy Davis/Race to Erase MS
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Served as a consultant for (1) Genzyme, (2) McKinsey & Co., (3) NKT Therapeutics, (4) Novartis Pharmaceuticals, (5) Bayer Yakuhin, Ltd., (6) Sage Therapeutics, (7) The Cleveland Clinic Foundation, (8) Bristol-Myers Squibb, (9) Juno Therapeutics, (10) Toray Industries
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Funded as PI or Co-PI by NIH grants (1) P01AI073748, 2008- 2013, (2)P01 AI045757,2013-2018, (3) R01 NS049477, 2010- 2015, (4) R01 AI091568, 2010-2015, (5) U19 AI089992, 2010- 2022,(6) P01 AI039671, 2010-2022, (7) R25 NS079193, 2012- 2022, (8) U01 AI02011, 2012-2017, (9) U01NS084495-01A1, 2013-2017, Funded as Co-PI by Department of the Army grant # MS110275, 2012-2013
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Funded as PI by (1) National Multiple Sclerosis Society grant # CA 1061-A-18, 2009-2019, (2) Nancy Taylor Foundation grant, 2011-2013
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
David Pitt, MD
From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.
Disclosure
Scientific Advisory Boards:
1.
(1) MedDay Pharma (2) EMD Serono
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
Astrocyte-Derived Exosomes as Biomarkers for Central Nervous System Diseases
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Biogen
Research Support, Government Entities:
1.
(1) NIH/NIAI 1 R21 AI149731-01 (PI) 02/01/2020 – 01/31/2022 (2) NIH/NINDS, R01 NS102267 (PI), 08/01/2017 – 05/31/2022 (3) NIH/NINDS, R01 NS105144 (co-I), 09/30/2018 – 08/31/2023 (4) NIH/NINDS R01 NS112907 (PI), 05/01/2019 – 03/31/2024
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
National Multiple Sclerosis Society
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence Dr. Pitt [email protected]
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
*
These authors contributed equally to this work.
The Article Processing Charge was funded by the NIH.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Julio F. Inocencio,
    • Stefan Mitrasinovic,
    • Mohammad Asad,
    • Ian F. Parney,
    • Xingxing Zang,
    • Benjamin T. Himes,
    Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape, Frontiers in Immunology, 15, (2024).https://doi.org/10.3389/fimmu.2024.1424396
    Crossref
    • Xi Chen,
    • Yi Cui,
    • Liqun Zou,
    Treatment advances in high-grade gliomas, Frontiers in Oncology, 14, (2024).https://doi.org/10.3389/fonc.2024.1287725
    Crossref
    • Yeteng Mu,
    • Xingang Guan,
    CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy, Current Medicinal Chemistry, 31, 13, (1634-1645), (2024).https://doi.org/10.2174/0929867330666230324152532
    Crossref
    • Wonyoung Jo,
    • Taejoon Won,
    • Abdel Daoud,
    • Daniela Čiháková,
    Immune checkpoint inhibitors associated cardiovascular immune-related adverse events, Frontiers in Immunology, 15, (2024).https://doi.org/10.3389/fimmu.2024.1340373
    Crossref
    • Somaya A. Abdel-Rahman,
    • Moustafa Gabr,
    Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma, Cancers, 16, 2, (435), (2024).https://doi.org/10.3390/cancers16020435
    Crossref
    • Jonathan D. Worboys,
    • Katherine N. Vowell,
    • Roseanna K. Hare,
    • Ashley R. Ambrose,
    • Margherita Bertuzzi,
    • Michael A. Conner,
    • Florence P. Patel,
    • William H. Zammit,
    • Judit Gali-Moya,
    • Khodor S. Hazime,
    • Katherine L. Jones,
    • Camille Rey,
    • Stipan Jonjic,
    • Tihana Lenac Rovis,
    • Gillian M. Tannahill,
    • Gabriela Dos Santos Cruz De Matos,
    • Jeremy D. Waight,
    • Daniel M. Davis,
    TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation, Nature Communications, 14, 1, (2023).https://doi.org/10.1038/s41467-023-40755-3
    Crossref
    • Junpeng Zhao,
    • Liming Li,
    • Huiqi Yin,
    • Xiwei Feng,
    • Qianjin Lu,
    TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer, International Immunopharmacology, 120, (110358), (2023).https://doi.org/10.1016/j.intimp.2023.110358
    Crossref
    • Imran Noorani,
    • Kastytis Sidlauskas,
    • Sean Pellow,
    • Reece Savage,
    • Jeannette L Norman,
    • David S Chatelet,
    • Mark Fabian,
    • Paul Grundy,
    • Jeng Ching,
    • James A R Nicoll,
    • Delphine Boche,
    Clinical impact of anti-inflammatory microglia and macrophage phenotypes at glioblastoma margins, Brain Communications, 5, 3, (2023).https://doi.org/10.1093/braincomms/fcad176
    Crossref
    • Carlo Pescia,
    • Giuditta Pini,
    • Edoardo Olmeda,
    • Stefano Ferrero,
    • Gianluca Lopez,
    TIGIT in Lung Cancer: Potential Theranostic Implications, Life, 13, 4, (1050), (2023).https://doi.org/10.3390/life13041050
    Crossref
    • Nouria Jantz-Naeem,
    • Romy Böttcher-Loschinski,
    • Katrin Borucki,
    • Marisa Mitchell-Flack,
    • Martin Böttcher,
    • Burkhart Schraven,
    • Dimitrios Mougiakakos,
    • Sascha Kahlfuss,
    TIGIT signaling and its influence on T cell metabolism and immune cell function in the tumor microenvironment, Frontiers in Oncology, 13, (2023).https://doi.org/10.3389/fonc.2023.1060112
    Crossref
  11. See more

View Options

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text HTML

View Full Text HTML
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

Figures

Tables

Media

Share

Share

Share article link

Share

View full text|Download PDF